Jpmorgan Chase & CO Decibel Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$2.41 - $4.81 $20,918 - $41,750	-8,680 Reduced 6.91%	116,981 $450,000
Q1 2023 May 11, 2023	SELL	$2.08 - $4.79 $10,214 - $23,523	-4,911 Reduced 3.76%	125,661 $379,000
Q4 2022 Feb 13, 2023	SELL	$1.86 - $3.54 $21,737 - $41,371	-11,687 Reduced 8.22%	130,572 $267,000
Q3 2022 Nov 14, 2022	SELL	$3.82 - $5.61 $22,786 - $33,463	-5,965 Reduced 4.02%	142,259 $492,000
Q2 2022 Aug 11, 2022	SELL	$1.85 - $4.21 $15,068 - $34,290	-8,145 Reduced 5.21%	148,224 $624,000

Q1 2022 May 11, 2022	SELL	$2.83 - $5.03 $11,761 - $20,904	-4,156 Reduced 2.59%	156,369 $476,000
Q4 2021 Feb 10, 2022	SELL	$4.57 - $8.58 $22,137 - $41,561	-4,844 Reduced 2.93%	160,525 $746,000
Q3 2021 Nov 12, 2021	BUY	$6.6 - $9.04 $1.09 Million - $1.49 Million	165,369 New	165,369 $1.28 Million

Ticker DBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,964,500
Description
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.